Retinal biomarkers and pharmacological targets for Hermansky-Pudlak syndrome 7

Sci Rep. 2020 Mar 4;10(1):3972. doi: 10.1038/s41598-020-60931-5.

Abstract

Deletion of dystrobrevin binding protein 1 has been linked to Hermansky-Pudlak syndrome type 7 (HPS-7), a rare disease characterized by oculocutaneous albinism and retinal dysfunction. We studied dysbindin-1 null mutant mice (Dys-/-) to shed light on retinal neurodevelopment defects in HPS-7. We analyzed the expression of a focused set of miRNAs in retina of wild type (WT), Dys+/- and Dys-/- mice. We also investigated the retinal function of these mice through electroretinography (ERG). We found that miR-101-3p, miR-137, miR-186-5p, miR-326, miR-382-5p and miR-876-5p were up-regulated in Dys-/-mice retina. Dys-/- mice showed significant increased b-wave in ERG, compared to WT mice. Bioinformatic analysis highlighted that dysregulated miRNAs target synaptic plasticity and dopaminergic signaling pathways, affecting retinal functions of Dys-/- mice. Overall, the data indicate potential mechanisms in retinal neurodevelopment of Dys-/- mice, which may have translational significance in HSP-7 patients, both in terms of diagnostic/prognostic biomarkers and novel pharmacological targets.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Computational Biology
  • Gene Expression Regulation / drug effects
  • Hermanski-Pudlak Syndrome / diagnosis
  • Hermanski-Pudlak Syndrome / drug therapy*
  • Hermanski-Pudlak Syndrome / genetics
  • Hermanski-Pudlak Syndrome / metabolism*
  • Mice
  • Mice, Inbred C57BL
  • MicroRNAs / blood
  • MicroRNAs / genetics
  • MicroRNAs / metabolism*
  • Molecular Targeted Therapy*
  • Prognosis
  • Retina / drug effects*
  • Retina / metabolism*

Substances

  • MicroRNAs